AZN logo

AZN
AstraZeneca PLC

18,840
Mkt Cap
$281.6B
Volume
1.38M
52W High
$212.71
52W Low
$137.23
PE Ratio
27.09
AZN Fundamentals
Price
$181.58
Prev Close
$184.96
Open
$183.25
50D MA
$191.98
Beta
0.43
Avg. Volume
2.06M
EPS (Annual)
$6.60
P/B
5.95
Rev/Employee
$611,227.89
$313,656.48
Loading...
Loading...
News
all
press releases
Top Stock Reports for Costco, Coca-Cola & AstraZeneca
Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift outlooks.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.
Zacks·1d ago
News Placeholder
Ralph Baric And UNC's Biodefense Contract Racket Exposed
Ralph Baric And UNC's Biodefense Contract Racket Exposed Authored by Paul D. Thacker via The DisInformation Chronicle, DLA Piper wants to get you, I was told, from a source in DC over the weekend...
Zero Hedge·2d ago
News Placeholder
Ralph Baric And UNC's Biodefense Contract Racket Exposed
Ralph Baric And UNC's Biodefense Contract Racket Exposed Authored by Paul D. Thacker via The DisInformation Chronicle, DLA Piper wants to get you, I was told, from a source in DC over the weekend...
Zero Hedge·2d ago
News Placeholder
Perioperative IMFINZI (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV...
Business Wire·2d ago
News Placeholder
Perioperative IMFINZI (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV...
Business Wire·2d ago
News Placeholder
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Zacks·3d ago
News Placeholder
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements
AstraZeneca reported positive Phase 3 CALYPSO data for eneboparatide in chronic hypoparathyroidism patients.read more...
Benzinga·4d ago
News Placeholder
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements
AstraZeneca reported positive Phase 3 CALYPSO data for eneboparatide in chronic hypoparathyroidism patients.read more...
Benzinga·4d ago
News Placeholder
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Zacks·8d ago
<
1
2
...
>

Latest AZN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.